Clinical Data

Pfizer and BioNTech Reach an Agreement to Supply the EU With 200 Million Doses of Their BNT162b2 mRNA-Based Vaccine Candidate Against SARS-CoV-2 | Business Wire | 11/11/2020

… preclinical and clinical studies, BNT162b1 and BNT162b2 emerged as strong candidates based on assessments of safety and immune response. On July 27, 2020, Pfizer and BioNTech announced that following extensive review of preclinical and clinical data from Phase 1/2 clinical trials, and in consultation with the FDA‚Äôs Center for Biologics Evaluation and Research (CBER) and other global regulators, the companies selected the BNT162b2 vaccine candidate to move forward into …

I-Mab Announces Preclinical Data on Differentiated Anti-C5aR Antibody TJ210/MOR210 at SITC 2020 | BioSpace | 11/11/2020

… looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding data from the TJ210 preclinical and clinical studies, the potential implications of clinical data for patients, and I-Mab’s advancement of, and anticipated clinical development, regulatory milestones and commercialization of TJ210. Actual results may differ materially from those indicated in the forward-looking statements as a result of …

Pfizer vaccine sees Zoom stock take a hit — what it means - TechHQ | 11/11/2020

… but stock market activity following the news of a potential Covid-19 vaccine on the horizon could suggest many are eager for some pre-2020 normalcy. After pharma giant Pfizer and BioNTech announced positive clinical data , their own shares rocketed, but so did those of move theatre chain AMC, concert promoter Live Nation, among those of large physical retailers, cruise lines, and online travel sites. READ NEXT ‚ÄòWe never felt …

Cleveland Clinic Makes COVID-19 Risk Prediction Model Available Through Epic | 11/11/2020

Working in partnership with Epic, through which it will be delivered, the Cleveland Clinic has released a new COVID-19 risk prediction model drawing on both patient entered data and clinical information. Researchers at the Cleveland Clinic developed and tested the model using clinical data from more than 11,000 of its patients. The Clinic used retrospective patient data from patients tested for COVID-19 at locations in Northeast Ohio and …

Intensity Therapeutics Reports Favorable Data of INT230-6 from the Ongoing Phase 1/2 Study (IT-01/KEYNOTE A10) in Patients with Advanced Solid Tumors at SITC 2020 (Abstract 411) | Business Wire | 11/11/2020

… of uninjected lesions in several patients provide early signs of anti-cancer efficacy. We are looking forward to the emerging data in combination with checkpoint inhibitors.‚Äù ‚ÄúWe are excited to share this interim clinical data of intratumoral INT230-6. There have been over 225 deep tumor injections without complications to date including dosing directly into the lung, liver, and pancreas. We and our investigators are increasing our understanding of a …

EXUMA Biotech Presents Preclinical Data on Rapid Point-of-Care “rPOC”Subcutaneous | BioSpace | 11/11/2020

EXUMA Biotech Presents Preclinical Data on Rapid Point-of-Care “rPOC”Subcutaneous Published: Nov 11, 2020 WEST PALM BEACH, Fla. , Nov. 11, 2020 /PRNewswire/ – EXUMA Biotech Corp., a clinical-stage biotechnology company discovering and developing CAR-T products and delivery solutions for liquid and solid tumors, today announced that preclinical data for the company’s next-generation rapid point-of-care, or “rPOC”, subcutaneous (SC) autologous CAR-T platform, are being …

Turning to natural alternatives for COVID-19 treatment | 11/11/2020

… work for critically ill patients. Further, another study done in New York, stated that using HCQ did not show extensive results and even induced certain side-effects that were not seen before. Based on clinical data , doctors using Favipiravir in the trials for Covid-19 observed that the drug suppressed the symptoms in people suffering from mild attacks of corona. However, Favipiravir does not offer total safety and the disease …

Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim Data | BioSpace | 11/10/2020

… ARCT-810, the ability to initiate or complete preclinical and clinical development programs, including as a result of the COVID-19 pandemic, the supply and delivery of any product or substance, the likelihood that clinical data will be predictive of future clinical results or sufficient for regulatory approval, the ability to enroll subjects in clinical trials, the Company‚Äôs efforts to develop a vaccine against COVID-19 and therapeutic potential …

NANOBIOTIX Announces Positive First Clinical Data Showing Conversion of Anti-PD-1 Non-Responders to Responders With Radioenhancer NBTXR3 | Markets Insider | Business Insider | 11/10/2020

… The product candidate is designed to increase the energy deposit from radiation therapy within the target tumor and subsequently increase the tumor-killing effect without increasing toxicity in surrounding healthy tissue. Pre-clinical and clinical data also suggest that NBTXR3 activated by radiation therapy can prime the immune system, creating an anti-tumor immune response that produces both local and systemic effects. A Phase I Study of Intratumoral NBTXR3 in …

Glympse Bio to Present Clinical Data at the AASLD 2020 Annual Meeting | PR Newswire | 11/10/2020

CAMBRIDGE, Mass. Glympse Bio (Glympse), a biotechnology company advancing the way diseases are understood, tracked, and treated, today announced that it will present clinical safety data from its First in Human healthy volunteer study, and data from a gene expression study of patients with advanced fibrosis at the American Association for the Study of Liver Disease (AASLD) 2020 Annual Meeting taking place virtually on Nov. 13-16. “We are developing our …

Glympse Bio to Present Clinical Data at the AASLD 2020 Annual Meeting | BioSpace | 11/10/2020

Glympse Bio to Present Clinical Data at the AASLD 2020 Annual Meeting CAMBRIDGE, Mass. , Nov. 10, 2020 /PRNewswire/ – Glympse Bio (Glympse), a biotechnology company advancing the way diseases are understood, tracked, and treated, today announced that it will present clinical safety data from its First in Human healthy volunteer study, and data from a gene expression study of patients with advanced fibrosis at the American Association for the Study of …

Innovative Cellular Therapeutics to Present CoupledCAR® Solid Tumor CAR-T Clinical Data at Upcoming Scientific Meetings | BioSpace | 11/10/2020

… a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for solid and liquid tumors, today announced its plans to present CoupledCAR¬Æ solid tumor CAR-T clinical data at two key oncology conferences. ICT will make data presentations at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) and at the American Society of Hematology …

FTSE 100 recovers to highest level since June after vaccine unveiled | London Stock Exchange | The Guardian | 11/10/2020

Promising clinical data from Pfizer and BioNTech help the index to a ¬£28bn one-day gain The London Stock Exchange closed at 6,296 on Tuesday, the highest since 23 June. Photograph: Facundo Arrizabalaga/EPA The London Stock Exchange closed at 6,296 on Tuesday, the highest since 23 June. Photograph: Facundo Arrizabalaga/EPA Tue 10 Nov 2020 19.45 GMT Last modified on Tue 10 Nov 2020 20.31 GMT Optimism that a …

FTSE 100 recovers to highest level since June after vaccine unveiled | Business | The Guardian | 11/10/2020

Promising clinical data from Pfizer and BioNTech help the index to a ¬£28bn one-day gain. Optimism that a mass rollout of Covid-19 vaccines will lead to an economic recovery lifted stocks in London again on Tuesday, to their highest closing level in over four months. London‚Äôs FTSE 100 index of blue-chip shares rallied by nearly 1.8% to finish at 6,296 points, the highest close since 23 …

Varian Medical Systems Invests in COTA, Inc. to Help Drive Faster, More Accurate Data-Driven Cancer Care | Yahoo News | 11/10/2020

Ä¢ November 10, 2020 PALO ALTO, Calif. , Nov. 10, 2020 /PRNewswire/ – Varian (NYSE: VAR) today announced a new $10M investment and collaboration agreement with COTA, Inc., a Boston -based curator of clinical data in oncology. Both companies will work together to empower cancer clinics with data analytics and decision support tools, using real-world evidence to help guide clinical and operational decisions as well as drive more cost-effective care …

New Alcon Innovations in Intraocular Lenses, Digital Health Solutions to be Showcased at the AAO 2020 Virtual Annual Meeting - news - Sparklight | 11/9/2020

… Presbyopia-Correcting Intraocular Lens from Two Large Confirmatory Studies. Presented by Dr. Devesh Varma PanOptix Trifocal IOL ‚Äì the first and only advanced trifocal lens approved in the U.S. ‚Äì will be featured in clinical data presentations reporting visual and refractive outcomes following implantation. Key presentations for the PanOptix Trifocal IOL at the meeting will include: Scientific Poster : Clinical Outcomes of a Diffractive Trifocal IOL with Femtosecond Laser-Assisted Cataract …

UroGen Pharma Reports Third Quarter 2020 Financial Results and Recent Corporate Developments | Business & Finance | heraldchronicle.com | Business Wire | 11/9/2020

PRINCETON, N.J.–(BUSINESS WIRE)–Nov 9, 2020– UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced financial results for the third quarter ended September 30, 2020 and provided an overview of the Company‚Äôs recent developments. ‚ÄúWe are excited to see the continued interest and uptake of Jelmyto for patients with low-grade upper tract …

Istari Oncology Presents Positive Data from Phase 1 Study of PVSRIPO in Patients with Unresectable Treatment Refractory Melanoma at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting | Business & Finance | heraldchronicle.com | Business Wire | 11/9/2020

DURHAM, N.C.–(BUSINESS WIRE)–Nov 9, 2020– Istari Oncology, Inc., a clinical-stage biotechnology company, today announced Phase 1 clinical data of its lead product candidate, PVSRIPO, for the treatment of patients with anti-PD-1 refractory melanoma at The Society for Immunotherapy of Cancer (SITC) 35 th Anniversary Annual Meeting being held virtually from November 9-14, 2020. This press release features multimedia. View the full release here: https://www.businesswire.com …

Surface Oncology to Present SRF388 and SRF114 Preclinical Data at the Upcoming Society for Immunotherapy for Cancer 2020 Virtual Conference | BioSpace | 11/9/2020

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) – Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that preclinical data on SRF388, a first in class IL-27 blocking antibody in clinical trials for patients with cancer, and SRF114, a CCR8-selective antibody, will be presented at the Society for Immunotherapy for Cancer‚Äôs (SITC) 35 th Anniversary Annual …

INFI: Infinity Pharmaceuticals Presents New MARIO-1 Phase 1/1b Clinical Data at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting | 11/9/2020

New alert via PocketInfo for INFI: Infinity Pharmaceuticals Presents New MARIO-1 Phase 1/1b Clinical Data at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting Press Releases: http://phx.corporate-ir.net/phoenix.zhtml?c=121941&p=irol-news&nyo=0 SEC Filings: http://phx.corporate-ir.net/phoenix.zhtml?c=121941&p=irol-sec Stock News Alerts by Pocket Info - the app Our free iPhone and iPad app lets you choose just …

BioXcel Therapeutics to Present BXCL701 Clinical Data at the Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting | BioSpace | 11/9/2020

NEW HAVEN, Conn., Nov. 09, 2020 (GLOBE NEWSWIRE) – BioXcel Therapeutics, Inc. (‚ÄúBTI‚Äù or ‚ÄúCompany‚Äù) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that two posters on BXCL701, the Company‚Äôs investigational, oral innate immunity activator, will be presented at the Society for Immunotherapy of Cancer’s (‚ÄúSITC‚Äù) 35 th Anniversary Annual Meeting being held from …

Agenus Presents Additional Clinical Responses and Novel Biomarker Data at SITC2020 | BioSpace | 11/9/2020

… other clinical-stage programs.‚Äù Presentation Highlights : AGEN1181 (Fc-enhanced CTLA-4) +/- balstilimab ( Agenus‚Äô anti-PD-1) show s additional clinical responses in tumors which are ‚Äúbiomarker unlikely‚Äù to respond; first - ever clinical data on i ntratumor al Treg depletion with a CTLA-4 antibody : CR in PD-L1(-) MSS endometrial cancer patient (1181 monotherapy) CR measured by PET in PD-L1(-) MSS endometrial cancer patient (1181 + bali …

4D Pharma Presents New Data from Two MRx0518 Clinical Trials at the Society for Immunotherapy of Cancer (SITC) Annual Meeting | BioSpace | 11/9/2020

LEEDS, England–( BUSINESS WIRE )– 4D Pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces new positive clinical data from two clinical trials of MRx0518, its lead immuno-oncology single strain Live Biotherapeutic candidate. The data is presented in three posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2020, November 9-14 …

Agenus Presents Additional Clinical Responses and Novel | StockTitan.net | 11/9/2020

… data on four other clinical-stage programs.” Presentation Highlights : AGEN1181 (Fc-enhanced CTLA-4) +/- balstilimab ( Agenus’ anti-PD-1) show s additional clinical responses in tumors which are “biomarker unlikely” to respond; first - ever clinical data on i ntratumor al Treg depletion with a CTLA-4 antibody : CR in PD-L1(-) MSS endometrial cancer patient (1181 monotherapy) CR measured by PET in PD-L1(-) MSS endometrial cancer patient (1181 + bali …

Evelo Biosciences Presents New Preclinical Data for Anti-Tumor Effects of Orally Delivered Microbial Extracellular Vesicles at the SITC 35th Anniversary Annual Meeting | BioSpace | 11/9/2020

EDP1908 demonstrates potent anti-tumor effects in murine models of cancer – – Oral e xtracellular vesicles have potential to be a completely novel mechanism of I/O therapy – CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) – Evelo Biosciences , Inc. (Nasdaq:EVLO) a clinical stage biotechnology company developing a new modality of orally delivered medicines which act in the small intestine with systemic effects, today announced preclinical data for EDP1908, its extracellular vesicle …